Abstract
Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.
Keywords: Microenvironment, mouse models, multiple myeloma, scaffolds, SCID-hu, SCID-rab, SCID-synth-hu, 5TMM, Bone marrow microenvironment, Bone marrow stromal cells, Non–obese diabetic.
Current Cancer Drug Targets
Title:Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma
Volume: 12 Issue: 7
Author(s): P. Tassone, P. Neri, R. Burger, M. T. Di Martino, E. Leone, N. Amodio, M. Caraglia and P. Tagliaferri
Affiliation:
Keywords: Microenvironment, mouse models, multiple myeloma, scaffolds, SCID-hu, SCID-rab, SCID-synth-hu, 5TMM, Bone marrow microenvironment, Bone marrow stromal cells, Non–obese diabetic.
Abstract: Mouse models of multiple myeloma (MM) are basic tools for translational research and play a fundamental role in the development of new therapeutics against plasma cell malignancies. All available models, including transplantable murine tumors in syngenic mice, xenografts of established human cell lines in immunocompromised mice and transgenic models that mirror specific steps of MM pathogenesis, have demonstrated some weaknesses in predicting clinical results, particularly for new drugs targeting the human bone marrow microenvironment (huBMM). The recent interest to models recapitulating the in vivo growth of primary MM cells in a human (SCID-hu) or humanized (SCID-synth-hu) host recipient has provided powerful platforms for the investigation of new compounds targeting MM and/or its huBMM. Here, we review and discuss strengths and weaknesses of the key in vivo models that are currently utilized in the MM preclinical investigation.
Export Options
About this article
Cite this article as:
Tassone P., Neri P., Burger R., T. Di Martino M., Leone E., Amodio N., Caraglia M. and Tagliaferri P., Mouse Models as a Translational Platform for the Development of New Therapeutic Agents in Multiple Myeloma, Current Cancer Drug Targets 2012; 12 (7) . https://dx.doi.org/10.2174/156800912802429292
DOI https://dx.doi.org/10.2174/156800912802429292 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Roles of Histone Deacetylases in Angiogenic Cellular Processes
Current Angiogenesis (Discontinued) Discovery and Hit to Lead Optimization of Novel Combretastatin A-4 Analogues: Dependence of C-Linker Length and Hybridization
Anti-Cancer Agents in Medicinal Chemistry Sphingolipid Signaling and Hematopoietic Malignancies: To the Rheostat and Beyond
Anti-Cancer Agents in Medicinal Chemistry Pharmacological Control of Autophagy: Therapeutic Perspectives in Inflammatory Bowel Disease and Colorectal Cancer
Current Pharmaceutical Design Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Marine Depsipeptides as Promising Pharmacotherapeutic Agents
Current Protein & Peptide Science Hippocampal Neurogenesis, Neurotrophic Factors and Depression: Possible Therapeutic Targets?
CNS & Neurological Disorders - Drug Targets Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Exploiting Endogenous Cellular Process to Generate Quinone Methides In Vivo
Current Organic Chemistry Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents
Current Medicinal Chemistry Fluorescence Imaging in Cancerology
Current Molecular Imaging (Discontinued) Application and Interpretation of Genome-Wide Association (GWA) Studies for Informing Pharmacogenomic Research - Examples from the Field of Age-Related Macular Degeneration
Current Molecular Medicine Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Functional Role of Glycosphingolipids in Cancer
Current Medicinal Chemistry 3-Bromopyruvic Acid, A Hexokinase II Inhibitor, is an Effective Antitumor Agent on the Hepatoma Cells : in vitro and in vivo Findings
Anti-Cancer Agents in Medicinal Chemistry Relevance of Protein Isoforms in Proteomic Studies
Current Proteomics The Role of PET/CT and SPECT/CT in Oncology Drug Development
Current Molecular Imaging (Discontinued) Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets QSAR and Docking Studies on Different Series of Histone Deacetylase Inhibitors (HDACIs)
Letters in Drug Design & Discovery